je.st
news
Tag: biotechnologies
Minerva Biotechnologies Licenses Sendai Virus Technology For Stem Cell Generation
2015-09-02 07:10:05| drugdiscoveryonline News Articles
Minerva Biotechnologies and ID Pharma Co., Ltd. (formerly DNAVEC) announced recently that they have signed an agreement granting Minerva worldwide rights to use and commercialize their non-integrating Sendai virus vectors, together with Minerva’s proprietary technology, for generating Induced Pluripotent Stem (iPS) cells
Tags: technology
cell
generation
virus
Minerva Biotechnologies Granted Worldwide License To iPS Technology
2015-08-05 06:57:21| drugdiscoveryonline Home Page
Minerva Biotechnologies and iPS Academia Japan, Inc. announced recently that they have signed an agreement granting Minerva worldwide rights to use and commercialize the induced Pluripotent Stem (iPS) cells patent portfolio arising from the work of Professor Shinya Yamanaka, MD, Ph.D., who won the Nobel Prize for Medicine in 2012 for his discovery of four genes that can reprogram an adult’s cell to go back in time to become that person’s own stem cell
Tags: technology
license
worldwide
granted
Cargill Acquires OPX Biotechnologies' Fermentation Technology
2015-05-05 12:31:09| Industrial Newsroom - All News for Today
MINNEAPOLIS and BOULDER, Colo. - Cargill has acquired Colorado-based OPX Biotechnologies' proprietary fermentation-based processes and systems. These technologies are used to produce bio-based chemicals from sugars for use in non-food applications such as lubricants, detergents, plastics, agrichemicals and personal...
Tags: technology
acquires
fermentation
biotechnologies
Cargill acquires OPX Biotechnologies fermentation-based processes and systems
2015-04-30 11:55:33| Green Car Congress
Tags: systems
processes
acquires
biotechnologies
Avalanche Biotechnologies: Unsustainable Price Presents Attractive Short Opportunity
2014-12-16 12:35:54| Biotech - Topix.net
When compared to its closest peer, the company appears to be significantly overvalued, and at more reasonable multiples Avalanche could see 50% downside. The stock has outrun its fundamentals, its story, and even optimistic analyst price targets, which positions it well for a short opportunity.
Tags: price
short
opportunity
presents